FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...
"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.
Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of side effects, a study suggests. Using AI, scientists found that images ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results